Alnylam Pharma (ALNY) Tops Q3 EPS by $3.06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nvidia's revenue forecast lifts Wall Street; investors eye the Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil jumps over $2 after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Revolution Medicines prices RASONQUE at $39,800 per month
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
November 2, 2023 8:00 AM EDTAchieved Third Quarter 2023 Global Net Product Revenues of $313 Million, Representing 35% Year-Over-Year Growth Compared to Q3 2022
Received Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Company Remains On Track to Report Topline Results from HELIOS-B Phase 3 Study in Early 2024
Reported Positive Topline Results from KARDIA-1 Phase 2 Study of Zilebesiran
Updated 2023 Guidance for Revenues from Collaborations and Royalties to $575 Million to $625 Million; Reiterated 2023 Guidance for Combined Net Product Revenues of $1,200 Million to... More
